share_log

Novo Nordisk CEO Says "Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide"; "When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity" For Obesity Drug; "Pleased With" The Catalent...

Benzinga ·  May 21 22:54

Novo Nordisk CEO Says "Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide"; "When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity" For Obesity Drug; "Pleased With" The Catalent Acquisition That We're Now Working On And We Expect To Close In This Year

- Reuters

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment